Research & Development
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union
26 July 2021 - - The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for US-based biotechnology company Moderna, Inc's (NASDAQ: MRNA) COVID-19 vaccine (Spikevax) to include adolescents 12 years of age and older, the company said. 

Spikevax is the trade name authorized by the European Medicines Agency for the Moderna COVID-19 vaccine.

Following the CHMP's positive opinion, the European Commission will consider authorizing the use of the Moderna COVID-19 Vaccine in adolescents ages 12 years of age and older.

On June 10, Moderna announced data from the ongoing Phase 2/3 study, which enrolled 3,732 participants ages 12 to less than 18 years in the US.

The study met its primary endpoint, successfully bridging immune responses to those observed in the COVE efficacy study in adults.

After two doses of the Moderna COVID-19 vaccine, no cases of COVID-19 were observed in the vaccine group using the case definition from the adult Phase 3 COVE study, compared to four cases in the placebo group, resulting in a vaccine efficacy of 100% starting 14 days after the second dose using the US Centers for Disease Control and Prevention's primary definition of COVID-19 infection.

The Moderna COVID-19 vaccine was generally well tolerated with a safety and tolerability profile consistent with the Phase 3 COVE study in adults.

The majority of adverse events were mild or moderate in severity. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events after the second dose of mRNA-1273 were headache, fatigue, myalgia and chills.
Safety data continue to accrue, and the study continues to be monitored by an independent safety monitoring committee. All participants will be monitored for 12 months after their second injection to assess long-term efficacy and safety.
The company will revise the age range to capture adolescent data in its ongoing and planned post-authorization studies.
Moderna has submitted data from the Phase 2/3 study to a peer-reviewed publication. These data have also been submitted to health authorities around the world and the company expects authorizations for adolescents in the coming weeks.
Moderna is also conducting a Phase 2/3 study, called the KidCOVE study, of mRNA-1273 in children ages 6 months to less than 12 years.
The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein.
On December 18, 2020, the US FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older.
Moderna has received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adults from health agencies in more than 50 countries and an Emergency Use Listing from the World Health Organization.
Moderna has filed for emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adolescents with global health agencies.
Spikevax (COVID-19 Vaccine Moderna) has been granted conditional marketing authorisation by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.


Related Headlines